Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
interleukin-22-secreting synthetic biotic
- Development stage
- Preclinical
- Lead developer
- Synlogic
- Modality
- Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Cytokines & Interferons → Recombinant Proteins and Enzymes
- Administration
- Oral
01
Overview
An **investigational live biotherapeutic microbial therapy** developed by **Synlogic** for **inflammatory bowel disease**. It consists of a genetically engineered **Escherichia coli Nissle 1917** chassis designed to **locally secrete human interleukin-22 in the gastrointestinal tract**, with the goal of driving mucosal repair and anti-inflammatory signaling in the gut while limiting systemic exposure. Preclinical presentations described **bioactive human IL-22 secretion**, recovery of IL-22 in feces and colon tissue, and induction of downstream IL-22-responsive genes such as **REG3B** and **BIRC5**, supporting local target engagement. The program appears to have remained **preclinical/undisclosed** rather than advancing as a named clinical candidate.
- Other names
- human IL-22-secreting synthetic bioticIL-22-secreting synthetic biotic medicineIL22-secreting synthetic biotic medicineIL 22-secreting synthetic biotic medicineEcN-IL22EcN-IL-22EcN-IL 22
02
Targets
IL-22R (Interleukin 22 Receptor)
Beyond the preview
Go deeper on interleukin-22-secreting synthetic biotic.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on interleukin-22-secreting synthetic biotic.